ATE316797T1 - Verfahren zur herstellung multivalenter impfstoffe - Google Patents

Verfahren zur herstellung multivalenter impfstoffe

Info

Publication number
ATE316797T1
ATE316797T1 AT97909341T AT97909341T ATE316797T1 AT E316797 T1 ATE316797 T1 AT E316797T1 AT 97909341 T AT97909341 T AT 97909341T AT 97909341 T AT97909341 T AT 97909341T AT E316797 T1 ATE316797 T1 AT E316797T1
Authority
AT
Austria
Prior art keywords
vaccine
components
component
composition
toxoid
Prior art date
Application number
AT97909341T
Other languages
English (en)
Inventor
Francois Arminjon
Jean-Rene Cartier
Sandrine Lentsch-Graf
Laurent Marchal
Original Assignee
Sanofi Pasteur Msd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Msd filed Critical Sanofi Pasteur Msd
Application granted granted Critical
Publication of ATE316797T1 publication Critical patent/ATE316797T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT97909341T 1997-09-15 1997-09-15 Verfahren zur herstellung multivalenter impfstoffe ATE316797T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1997/005378 WO1999013906A1 (en) 1997-09-15 1997-09-15 Multivalent vaccines

Publications (1)

Publication Number Publication Date
ATE316797T1 true ATE316797T1 (de) 2006-02-15

Family

ID=8166750

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97909341T ATE316797T1 (de) 1997-09-15 1997-09-15 Verfahren zur herstellung multivalenter impfstoffe

Country Status (10)

Country Link
EP (1) EP1028750B1 (de)
AT (1) ATE316797T1 (de)
AU (1) AU4707097A (de)
BR (1) BR9714980A (de)
CA (1) CA2303105A1 (de)
DE (1) DE69735191T2 (de)
DK (1) DK1028750T3 (de)
ES (1) ES2257769T3 (de)
PT (1) PT1028750E (de)
WO (1) WO1999013906A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004314A1 (de) * 1998-11-26 2000-05-31 Pasteur Merieux MSD T.d.Polio Impstoff für einer primovakzinierter oder empfindlicher Population
KR100374813B1 (ko) * 2000-04-07 2003-03-03 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드, 정제백일해 및비형간염표면항원을 포함한 4가 혼합백신 및 그 제조 방법
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
EP1946769B1 (de) 2000-06-29 2012-05-30 SmithKline Beecham Biologicals S.A. Multivalente Impfstoffzusammensetzung mit niedriger Dose von Haemophilus influenzae Typ B
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
US7927858B2 (en) 2002-11-01 2011-04-19 Glaxosmithkline Biologicals, S.A. Drying process
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
KR20130122810A (ko) 2005-06-27 2013-11-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
US8124397B2 (en) 2005-08-08 2012-02-28 Oregon Health & Science University Inactivating pathogens with oxidizing agents for vaccine production
GB0616306D0 (en) * 2006-08-16 2006-09-27 Novartis Ag Vaccines
PL2066344T3 (pl) † 2006-09-07 2011-10-31 Glaxosmithkline Biologicals Sa Skojarzona szczepionka zawierająca inaktywowany wirus polio
PE20100366A1 (es) 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
EP3459562B1 (de) 2011-01-05 2024-03-20 Bharat Biotech International Limited Siebenwertiger kombinationsimpfstoff
FR2985663B1 (fr) * 2012-01-17 2015-03-27 Sanofi Pasteur Procede de formulation d'un vaccin contenant au moins deux antigenes susceptibles de s'adsorber sur de l'oxy hydroxyde d'aluminium
SG11201502599TA (en) * 2012-10-12 2015-05-28 Glaxosmithkline Biolog Sa Non-cross-linked acellular pertussis antigens for use in combination vaccines
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN105646726A (zh) * 2016-02-03 2016-06-08 成都康华生物制品有限公司 一种b型流感嗜血杆菌荚膜多糖的制备方法及联合疫苗
CA3070039A1 (en) 2017-07-18 2019-01-24 Serum Institute Of India Pvt Ltd. An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
JOP20190242A1 (ar) 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
GB2619625B (en) 2019-05-20 2024-04-03 Soligenix Inc Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines
EP4327820A1 (de) 2021-04-20 2024-02-28 KM Biologics Co., Ltd. Flüssige sextupel-impfstoffzusammensetzung

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE168271T1 (de) * 1992-05-23 1998-08-15 Smithkline Beecham Biolog Kombinierte impfstoffe, die hepatitis b oberfläche antigen und andere antigenen enthalten
SK283565B6 (sk) * 1996-07-02 2003-09-11 Connaught Laboratories Limited Multivalentná imunogénna kompozícia a jej použitie

Also Published As

Publication number Publication date
CA2303105A1 (en) 1999-03-25
PT1028750E (pt) 2006-05-31
WO1999013906A1 (en) 1999-03-25
EP1028750B1 (de) 2006-02-01
EP1028750A1 (de) 2000-08-23
DK1028750T3 (da) 2006-05-22
DE69735191D1 (de) 2006-04-13
ES2257769T3 (es) 2006-08-01
DE69735191T2 (de) 2006-10-05
BR9714980A (pt) 2001-11-06
AU4707097A (en) 1999-04-05

Similar Documents

Publication Publication Date Title
ATE316797T1 (de) Verfahren zur herstellung multivalenter impfstoffe
DE69736709D1 (de) Vielwertige dtp-polio-impfstoffe
HU1000593D0 (en) Vaccine compositions
LU91658I2 (fr) Vaccin combiné diphtérique, tétanique, coquelucheux, hépatite B, poliomyélitique et Haemophilus influenzae type B conjugué (INFANRIX HEXA®)
RU2009105117A (ru) Композиции, включающие антигены neisseria meningitidis из серогрупп в и с, и дополнительный антиген
SI1835939T1 (sl) Cepljenje na osnovi meningokoknih konjugatov
PL1740217T3 (pl) Szczepienie koniugatem meningokokowym
CA2277141A1 (en) Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this procedure
UA27754C2 (uk) Комбінована педіатрична вакцина, спосіб одночасної комбінованої вакцинації
AU2001269569A1 (en) Quadrivalent combination vaccine including diphtheria toxoid, tetanus toxoid, whole cell pertussis and hepatitis surface antigen, and preparation method thereof
WO2000051633A3 (en) MULTI-COMPONENT VACCINE COMPRISING AT LEAST THREE ANTIGENS TO PROTECT AGAINST DISEASE CAUSED BY $i(HAEMOPHILUS INFLUENZAE)
DK1200122T3 (da) Multikomponentvaccine til beskyttelse mod sygdom, som er forårsaget af Haemophilus influenzae og Moraxella catarrhalis
GB9611501D0 (en) Vaccine compositions

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1028750

Country of ref document: EP